Abstract
Plasmablastic lymphoma (PBL) is a rare distinct subtype of aggressive diffuse large B-cell lymphoma and a notoriously hard to treat entity with a dismal prognosis in both HIV-negative and HIV-positive patients. Clinicians often face the question of second or third line treatment. As the treatment options with novel agents in lymphomas are rapidly evolving, more and more options beyond standard chemotherapy are available. In connection with a review of treatment options with novel lymphoma agents, we present a case report of a patient with a complete remission after the administration of brentuximab vedotin and lenalidomide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125(15):2323–2330
Vega F et al (2005) Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18(6):806–815
Holderness BM et al (2013) Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol 31(12):e197–e199
Carras S et al (2015) Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Leuk Lymphoma 56(10):2986–2988
Bibas M et al (2010) Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 28(34):e704–e708
Bibas M, Castillo JJ (2014) Current knowledge on HIV-associated plasmablastic lymphoma. Mediterr J Hematol Infect Dis 6(1):e2014064
Loghavi S et al (2015) Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol 8:65
Al-Malki MM et al (2014) Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant 20(12):1877–1884
Robak T et al (2015) Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372(10):944–953
Fernandez-Alvarez R et al (2015) Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leuk Lymphoma:1–4
Fedele PL et al (2016) Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol 95(4):667–668
Castillo JJ et al (2015) Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol 169(3):352–355
Colomo L et al (2004) Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 28(6):736–747
Forero-Torres A et al (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126(26):2798–2804
Fang C et al (2015) Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis. Int J Clin Exp Med 8(7):10705–10713
Yanamandra U et al (2016) Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings. Ann Hematol 95(10):1715–1717
Authors contributions
Alexander Kalisch and Dominik Pretscher performed the research.
Josef Birkmann and Martin Wilhelm analyzed the data.
Dominik Pretscher, Alexander Kalisch, and Martin Wilhelm wrote the paper.
Compliance with ethical standards
ᅟ
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
An ethics approval is not available.
Consent to participate
A consent to publish is not available due to the death of the patient.
Availability of data and material
We are not allowed to publish the patient’s complete datasets due to legal reasons.
Funding
No funding supported this study.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Pretscher, D., Kalisch, A., Wilhelm, M. et al. Refractory plasmablastic lymphoma—a review of treatment options beyond standard therapy. Ann Hematol 96, 967–970 (2017). https://doi.org/10.1007/s00277-016-2904-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2904-7